We are live on ! Find out more
EW icon

Edwards Lifesciences

557 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 194 increasing their positions, 181 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

24% more capital invested

Capital invested by funds: $9.47B → $11.7B (+$2.24B)

12% more funds holding

Funds holding: 497557 (+60)

7% more repeat investments, than reductions

Existing positions increased: 194 | Existing positions reduced: 181

7.26% less ownership

Funds ownership: 522.92%515.66% (-7.3%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
557
Holders Change
+60
Holders Change %
+12.07%
% of All Funds
14.79%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
194
Reduced
181
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M

EW Hedge Fund Activity: Q4 2014 in Review

557 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — up 24% from $9.47B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 194 added to existing stakes and 181 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 557 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 497 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, up 24% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.